ABBOTT BIOTHERAPEUTICS CORP.
Patent Owner
Stats
- 18 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Jan 20, 2015 most recent publication
Details
- 18 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,393 Total Citation Count
- Apr 08, 1992 Earliest Filing
- 13 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
8017116 Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesisAug 17, 07Sep 13, 11[A61K, C12N, A61P]
7935793 Treatment of inflammatory bowel diseases with anti-IP-10 antibodiesNov 10, 04May 03, 11[A61K, C07K]
7842293 Compositions and methods using anti-CS1 antibodies to treat multiple myelomaAug 07, 07Nov 30, 10[A61K, C12N, A61P]
7365168 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisApr 08, 05Apr 29, 08[C12P]
7361740 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisApr 09, 04Apr 22, 08[C12P]
7217797 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesisOct 15, 03May 15, 07[C12P]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2013/0058,921 USE OF AUTOLOGOUS EFFECTOR CELLS AND ANTIBODIES FOR TREATMENT OF MULTIPLE MYELOMAAbandonedOct 30, 09Mar 07, 13[A61K, A61P]
2011/0165,154 COMPOSITIONS AND METHODS USING ANTI-CS1 ANTIBODIES TO TREAT MULTIPLE MYELOMAAbandonedOct 12, 10Jul 07, 11[A61K, C12N, A61P]
2011/0104,153 USE OF IMMUNOREGULATORY NK CELL POPULATIONS FOR PREDICTING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTSAbandonedOct 29, 10May 05, 11[A61K, C12Q, A61P]
2011/0070,231 STABLE LIQUID PHARMACEUTICAL FORMULATION OF IGG ANTIBODIESAbandonedNov 24, 10Mar 24, 11[A61K]
2011/0053,209 USE OF AN IMMUNOREGULATORY NK CELL POPULATION FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTSAbandonedAug 31, 10Mar 03, 11[C12Q]
2010/0291,111 Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell ProliferationAbandonedDec 18, 09Nov 18, 10[A61K, A61P]
2010/0273,204 METHODS FOR MONITORING THE EFFICACY OF ANTI-IL-2R ANTIBODIES IN MULTIPLE SCLEROSIS PATIENTSAbandonedApr 27, 10Oct 28, 10[C12Q]
2010/0074,841 Compositions Against Cancer Antigen LIV-1 and Uses ThereofAbandonedNov 19, 09Mar 25, 10[A61K, C12N, C07K]
2010/0055,098 METHOD FOR TREATING MULTIPLE SCLEROSIS PATIENTS WITH ANTI-IL2R ANTIBODIESAbandonedAug 28, 09Mar 04, 10[A61K]
7662384 Use of anti-α5β1 antibodies to inhibit cancer cell proliferationExpiredMar 24, 05Feb 16, 10[A61K]
2003/0138,417 Stable liquid pharmaceutical formulation of IgG antibodiesAbandonedNov 08, 02Jul 24, 03[A61K]
2002/0194,631 Method of treating psoriasis using anti-interleukin 12 antibodyAbandonedMar 26, 02Dec 19, 02[A61K, A01K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.